Andrew J. Roth | Authors

Articles

Study Shows Promising Results in Using Midostaurin to Treat Advanced Mastocytosis

August 30, 2016

According to phase II findings published in The New England Journal of Medicine1, multikinase inhibitor midostaurin (PKC412) demonstrated an overall response rate (ORR) of 60% in patients with advanced systemic mastocytosis.